Systemic therapy for elderly patients with gastrointestinal cancer

Joleen M. Hubbard; Axel Grothey; Daniel J. Sargent

doi:10.4137/CMO.S6983

Systemic therapy for elderly patients with gastrointestinal cancer

Joleen M. Hubbard, Axel Grothey, Daniel J. Sargent

Research output: Contribution to journal › Review article › peer-review

4 Scopus citations

Abstract

The majority of patients with gastrointestinal cancers are over the age of 65. This age group comprises the minority of the patients enrolled in clinical trials, and it is unknown whether older patients achieve similar results as younger patients in terms of survival benefit and tolerability. In addition, there are few studies specifically designed for patients over 65 years. Subset analyses of individual trials and studies using pooled patient data from multiple trials provide some understanding on outcomes in older patients with gastrointestinal cancers. This article reviews the evidence on chemotherapeutic regimens in the elderly with colorectal, pancreatic, and gastroesophageal cancers, and discusses a practical approach to provide the best outcomes for older patients.

Original language	English (US)
Pages (from-to)	89-99
Number of pages	11
Journal	Clinical Medicine Insights: Oncology
Volume	5
DOIs	https://doi.org/10.4137/CMO.S6983
State	Published - 2011

Keywords

Adjuvant therapy
Gastrointestinal cancers
Geriatric oncology
Neoadjuvant therapy
Perioperative therapy

ASJC Scopus subject areas

Oncology

Access to Document

10.4137/CMO.S6983

Cite this

@article{2d88e6d47b6948f2b453f17272772889,

title = "Systemic therapy for elderly patients with gastrointestinal cancer",

abstract = "The majority of patients with gastrointestinal cancers are over the age of 65. This age group comprises the minority of the patients enrolled in clinical trials, and it is unknown whether older patients achieve similar results as younger patients in terms of survival benefit and tolerability. In addition, there are few studies specifically designed for patients over 65 years. Subset analyses of individual trials and studies using pooled patient data from multiple trials provide some understanding on outcomes in older patients with gastrointestinal cancers. This article reviews the evidence on chemotherapeutic regimens in the elderly with colorectal, pancreatic, and gastroesophageal cancers, and discusses a practical approach to provide the best outcomes for older patients.",

keywords = "Adjuvant therapy, Gastrointestinal cancers, Geriatric oncology, Neoadjuvant therapy, Perioperative therapy",

author = "Hubbard, {Joleen M.} and Axel Grothey and Sargent, {Daniel J.}",

year = "2011",

doi = "10.4137/CMO.S6983",

language = "English (US)",

volume = "5",

pages = "89--99",

journal = "Clinical Medicine Insights: Oncology",

issn = "1179-5549",

publisher = "Libertas Academica Ltd.",

}

TY - JOUR

T1 - Systemic therapy for elderly patients with gastrointestinal cancer

AU - Hubbard, Joleen M.

AU - Grothey, Axel

AU - Sargent, Daniel J.

PY - 2011

Y1 - 2011

N2 - The majority of patients with gastrointestinal cancers are over the age of 65. This age group comprises the minority of the patients enrolled in clinical trials, and it is unknown whether older patients achieve similar results as younger patients in terms of survival benefit and tolerability. In addition, there are few studies specifically designed for patients over 65 years. Subset analyses of individual trials and studies using pooled patient data from multiple trials provide some understanding on outcomes in older patients with gastrointestinal cancers. This article reviews the evidence on chemotherapeutic regimens in the elderly with colorectal, pancreatic, and gastroesophageal cancers, and discusses a practical approach to provide the best outcomes for older patients.

AB - The majority of patients with gastrointestinal cancers are over the age of 65. This age group comprises the minority of the patients enrolled in clinical trials, and it is unknown whether older patients achieve similar results as younger patients in terms of survival benefit and tolerability. In addition, there are few studies specifically designed for patients over 65 years. Subset analyses of individual trials and studies using pooled patient data from multiple trials provide some understanding on outcomes in older patients with gastrointestinal cancers. This article reviews the evidence on chemotherapeutic regimens in the elderly with colorectal, pancreatic, and gastroesophageal cancers, and discusses a practical approach to provide the best outcomes for older patients.

KW - Adjuvant therapy

KW - Gastrointestinal cancers

KW - Geriatric oncology

KW - Neoadjuvant therapy

KW - Perioperative therapy

UR - http://www.scopus.com/inward/record.url?scp=79958022753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958022753&partnerID=8YFLogxK

U2 - 10.4137/CMO.S6983

DO - 10.4137/CMO.S6983

M3 - Review article

C2 - 21603244

AN - SCOPUS:79958022753

SN - 1179-5549

VL - 5

SP - 89

EP - 99

JO - Clinical Medicine Insights: Oncology

JF - Clinical Medicine Insights: Oncology

ER -

Systemic therapy for elderly patients with gastrointestinal cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this